CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Upgrade

The rating of CRISPR Therapeutics AG (NASDAQ:CRSP) was increased today by equity research analysts at BidaskScore to a “Buy” rating in a report.

CRISPR Therapeutics AG (NASDAQ:CRSP) Ratings Coverage

Among 4 analysts covering CRISPR Therapeutics AG – Common Shares (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CRISPR Therapeutics AG – Common Shares has $8000 highest and $5000 lowest target. $66.50’s average target is -7.19% below currents $71.65 stock price. CRISPR Therapeutics AG – Common Shares had 6 analyst reports since June 10, 2019 according to SRatingsIntel. Oppenheimer upgraded CRISPR Therapeutics AG (NASDAQ:CRSP) rating on Tuesday, November 12. Oppenheimer has “Outperform” rating and $6500 target. The stock has “Outperform” rating by Oppenheimer on Tuesday, November 26.

The stock increased 5.20% or $3.54 during the last trading session, reaching $71.65. About 1.01 million shares traded or 23.79% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has risen 7.51% since November 30, 2018 and is uptrending. It has outperformed by 7.51% the S&P500.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on February, 24. They expect $0.04 earnings per share, up 104.35 % or $0.96 from last year’s $-0.92 per share. CRSP’s profit will be $2.25M for 447.81 P/E if the $0.04 EPS becomes a reality. After $2.40 actual earnings per share reported by CRISPR Therapeutics AG for the previous quarter, Wall Street now forecasts -98.33 % negative EPS growth.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $4.03 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

More notable recent CRISPR Therapeutics AG (NASDAQ:CRSP) news were published by: Benzinga.com which released: “Stocks That Hit 52-Week Highs On Tuesday – Benzinga” on November 12, 2019, also Fool.com with their article: “Is CRISPR Therapeutics the Best Gene-Editing Stock Right Now? – The Motley Fool” published on November 26, 2019, Fool.com published: “Here’s Why Crispr Therapeutics Gained 22.8% in October – Motley Fool” on November 07, 2019. More interesting news about CRISPR Therapeutics AG (NASDAQ:CRSP) were released by: Nasdaq.com and their article: “Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal – Nasdaq” published on November 13, 2019 as well as Benzinga.com‘s news article titled: “7 Stocks To Watch For November 20, 2019 – Benzinga” with publication date: November 20, 2019.

CRISPR Therapeutics AG (NASDAQ:CRSP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link